SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: AFFYMETRIX (AFFX)

No earlier versions found for this Subject.


Return to AFFYMETRIX (AFFX)
 
Affymetrix is a spin-off of Affymax. Does anyone have any knowledge
of this company? (I will also post this to the IPO forum)

-jed
(Sorry, no word wrap)

FOR IMMEDIATE RELEASE
FOR FURTHER INFORMATION CONTACT:

Kenneth J. Nussbacher
Executive Vice President and Chief Financial Officer
Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051
(408) 522-6000

AFFYMETRIX, INC. FILES REGISTRATION
STATEMENT FOR INITIAL PUBLIC OFFERING

Santa Clara, CA, April 15, 1996. Affymetrix, Inc., ("Affymetrix" or the
"Company"; proposed Nasdaq National Market Symbol: AFFX) announced today that i
t has filed a registration statement with the Securities and Exchange Commission
for an initial public offering of 5,000,000 shares of Common Stock. The offeri
ng price is expected to be between $11.00 and $13.00 per share. All of the shar
es are being sold by Affymetrix. The Company will have 21,166,266 shares of Com
mon Stock outstanding after the offering. The offering will be managed by Robert
son, Stephens & Company LLC, CS First Boston Corporation and Montgomery Securiti
es.

Affymetrix has developed and intends to establish its GeneChip8 system a
s the platform of choice for acquiring, analyzing and managing complex genetic i
nformation in order to improve the diagnosis, monitoring and treatment of diseas
e. The Company's GeneChip8 system consists of disposable DNA probe arrays contai
ning gene sequences on a chip, instruments to process the probe arrays, and soft
ware to analyze and manage genetic information. The Company is commencing commer
cial sales of the GeneChip8 system and an HIV probe array for research use in Ap
ril 1996.

The net proceeds to the Company from the offering will be used for produ
ct development, manufacturing scale-up, research, sales and marketing and capita
l equipment, as well as for working capital and other general corporate purposes
.

A registration statement relating to these securities has been filed wit
h the Securities and Exchange Commission but has not yet become effective. The s
ecurities may not be sold nor may offers to buy be accepted prior to the time th
e registration statement becomes effective. This press release shall not consti
tute an offer to sell or a solicitation of an offer to buy nor shall there be an
y sale of these securities in any state or jurisdiction in which such offer, sol
icitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.

Copies of the preliminary prospectus relating to the offering may be obt
ained from Robertson, Stephens & Company LLC, 555 California Street, Suite 2600,
San Francisco, CA 94104, (415) 781-9700; CS First Boston Corporation, 55 East 5
2nd Street, New York, NY 10055, (212) 909-2000; or Montgomery Securities, 600 Mo
ntgomery Street, San Francisco, CA 94111, (415) 627-2000.